“Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties.
The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.
After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician.
These findings suggest that CBD has beneficial effects in patients with schizophrenia. As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”
https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2017.17030325
“Cannabis ingredient holds promise as antipsychotic medicine” https://www.reuters.com/article/us-health-cannabis-psychosis/cannabis-ingredient-holds-promise-as-antipsychotic-medicine-idUSKBN1E90P6